Chris Raymond
Stock Analyst at Raymond James
(2.98)
# 1,347
Out of 5,147 analysts
9
Total ratings
66.67%
Success rate
64.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Outperform | $142 → $123 | $54.81 | +124.43% | 3 | Nov 14, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $36.54 | +23.15% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $33.31 | +5.07% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $101.95 | +2.99% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $10.46 | +119.89% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $38.85 | -22.78% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $11.52 | +551.04% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Nov 14, 2025
Downgrades: Outperform
Price Target: $142 → $123
Current: $54.81
Upside: +124.43%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $36.54
Upside: +23.15%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $33.31
Upside: +5.07%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $101.95
Upside: +2.99%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $10.46
Upside: +119.89%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $38.85
Upside: -22.78%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $11.52
Upside: +551.04%